PRESS RELEASE published on 07/08/2024 at 23:15, 1 year 7 months ago Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement Theralase® closes successful Non-Brokered Private Placement offering to fund cancer research and clinical studies. Proceeds to advance Phase II NMIBC study and Rutherrin® development Non-brokered Private Placement Theralase Technologies Inc. Cancer Research Rutherrin® Phase II NMIBC Study
BRIEF published on 06/20/2024 at 13:05, 1 year 7 months ago Theralase Successfully Repurposes Non-Cancer Drugs for Cancer Therapy Cancer Therapy Theralase Rutherrin Drug Repurposing Preclinical Research
BRIEF published on 06/20/2024 at 13:05, 1 year 7 months ago Theralase réutilise avec succès des médicaments non anticancéreux pour le traitement du cancer Recherche Préclinique Thérapie Contre Le Cancer Theralase Rutherrin Réutilisation De Médicaments
PRESS RELEASE published on 06/20/2024 at 13:00, 1 year 7 months ago Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy Theralase® Technologies Inc. announces successful preclinical research in drug repurposing for cancer therapy using Rutherrin®, demonstrating increased efficacy in destroying cancer cells Theralase Technologies Inc. Cancer Therapy Rutherrin Drug Repurposing Preclinical Research
BRIEF published on 06/19/2024 at 13:05, 1 year 7 months ago Rutherrin® Demonstrates Complete Response in Lung Cancer Preclinically Preclinical Study Theralase Lung Cancer Rutherrin Tumor Regression
BRIEF published on 06/19/2024 at 13:05, 1 year 7 months ago Rutherrin® démontre une réponse complète dans le cancer du poumon au niveau préclinique Theralase Cancer Du Poumon Étude Préclinique Rutherrin Régression Tumorale
PRESS RELEASE published on 06/19/2024 at 13:00, 1 year 7 months ago Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically Theralase® Technologies Inc. announces promising results of Rutherrin® in treating Non-Small Cell Lung Cancer animal model with x-ray activation. Research shows tumor regression & improved survival rates Theralase® Technologies Inc. Rutherrin® Tumor Regression Non-Small Cell Lung Cancer X-ray Activation
BRIEF published on 06/18/2024 at 13:05, 1 year 7 months ago Rutherrin® Enhances Immunotherapy Efficacy in Preclinical Studies Cancer Treatment Theralase® Immunotherapy Rutherrin® Checkpoint Inhibitors
BRIEF published on 06/18/2024 at 13:05, 1 year 7 months ago Rutherrin® améliore l'efficacité de l'immunothérapie dans les études précliniques Theralase® Immunothérapie Traitement Du Cancer Rutherrin® Inhibiteurs De Points De Contrôle
PRESS RELEASE published on 06/18/2024 at 13:00, 1 year 7 months ago Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically Theralase Technologies Inc. announces preclinical research results showing Rutherrin® enhances immunotherapy efficacy by reducing PD-L1 proteins in cancer cells. The advancement aims to improve cancer treatment outcomes Theralase Technologies Inc. Cancer Treatment Immunotherapy Rutherrin PD-L1 Proteins
Published on 02/11/2026 at 14:35, 7 hours 52 minutes ago Worksport Delivers Breakout Q4: Revenue Up 65% YoY, Gross Profit Up 380%
Published on 02/11/2026 at 14:30, 7 hours 57 minutes ago Sekur Private Data CEO Updates on Growth, Market Expansion, Corporate Developments and New Product Launch
Published on 02/11/2026 at 14:00, 8 hours 27 minutes ago Organto Foods Inc. Expands Scalable and Flexible Logistics Platform to Support 2026 Growth
Published on 02/11/2026 at 14:00, 8 hours 27 minutes ago PPX Mining Provides Operational and Corporate Update
Published on 02/11/2026 at 14:00, 8 hours 27 minutes ago Meta Critical Minerals Engages Quad Consulting Group to Advance Table Mountain Silica Project Development Strategy
Published on 02/11/2026 at 19:52, 2 hours 35 minutes ago LR Health & Beauty SE lays foundation for positive future business performance with new financing structure
Published on 02/11/2026 at 19:50, 2 hours 37 minutes ago EQS-Adhoc: LR HEALTH & BEAUTY SE REACHES AN AGREEMENT WITH BONDHOLDERS AND SHAREHOLDER REGARDING A COMPREHENSIVE RESTRUCTURING OF THE 2024/2028 BOND – EUR 20 MILLION IN NEW CAPITAL AND ...
Published on 02/11/2026 at 18:31, 3 hours 56 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/11/2026 at 18:00, 4 hours 27 minutes ago Private Equity Holding AG: Net Asset Value as of January 31, 2026
Published on 02/11/2026 at 17:45, 4 hours 42 minutes ago Infotel : Stake held in AeroEx. A publisher of digital compliance and safety solutions for the aerospace industry.
Published on 02/11/2026 at 17:45, 4 hours 42 minutes ago Infotel : Prise de participation dans AeroEx éditeur de solutions digitales de conformité et de sécurité pour l’industrie aéronautique.
Published on 02/11/2026 at 11:25, 11 hours 2 minutes ago Innelec : Mise à disposition du rapport financier semestriel 2025-26
Published on 02/11/2026 at 08:00, 14 hours 27 minutes ago Imerys-press-release French State acquisition stake Emili Lithium
Published on 02/11/2026 at 08:00, 14 hours 27 minutes ago Imerys-communique-de-presse prise participation Etat Français Projet lithium Emili
